Reminder: Visit Plus Therapeutics at #SABCS2024 in San Antonio – Booth #1542!
Join us at #SABCS2024 in San Antonio, Texas, where Plus Therapeutics will be showcasing its groundbreaking work in targeted radiation therapy for central nervous system cancers including leptomeningeal disease. Visit us at Booth #1542 to learn more about Rhenium (186Re) Obisbemeda, our innovative treatment designed for Leptomeningeal Metastases (LM), a rare but serious complication in cancer patients.
What is Leptomeningeal Metastases (LM)?
Leptomeningeal Metastases occurs when cancer cells spread to the membranes surrounding the brain and spinal cord, causing a challenging and often aggressive form of cancer. LM is most commonly found in patients with breast cancer, lung cancer, gastrointestinal cancers, and melanoma. At Plus Therapeutics, we are working to change the treatment landscape for this rare condition with Rhenium (186Re) Obisbemeda, an advanced radiotherapy approach that targets cancer cells in the central nervous system.
For more information on our ReSPECT-LM clinical trial and how we are addressing this unmet medical need, visit:
ReSPECT-LM Clinical Trials
Why Visit Booth #1542?
- Discover cutting-edge treatments for Leptomeningeal Metastases and other central nervous system cancers.
- Learn about Rhenium (186Re) Obisbemeda and its potential to improve outcomes for patients with metastatic cancers.
- Meet our team and discuss collaboration opportunities in the field of oncology and therapeutics.
#SABCS2024 #BreastCancer #MetastaticCancer #LeptomeningealMetastases #Radiotherapy #CancerTreatment #OncologyResearch #CNSCancers #RheniumObisbemeda #Therapeutics #RareDiseases #CancerTherapies #MedicalInnovation #CancerAwareness #PSTV #CentralNervousSystemCancers #CancerCare #TargetedTherapy
Recent Comments